ENGLEWOOD, Colo., Jan. 22, 2015 /PRNewswire/ -- Luoxis Diagnostics, Inc., a subsidiary of Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today announced it has secured long-term agreements with European distributors Eurobio, Una Health Limited, and THP Medical, to offer Luoxis' RedoxSYS™ Diagnostic System to prominent academic and pharma-based research centers within their respective territories. RedoxSYS is a first-in-class diagnostic platform and robust research tool capable of measuring oxidation-reduction potential (ORP) in the body in response to injury, illness, or stress.
Under the terms of the agreements, Eurobio was granted territorial rights to offer RedoxSYS to institutions based in France and Switzerland, while Una Health Limited and THP Medical were granted territorial rights to the United Kingdom and Austria, respectively. These are multi-year agreements with the option to renew at the 3-5 year mark. As a whole, the customer base for Luoxis' initial EU distribution network includes notable research centers, such as The French National Centre for Scientific Research (CNRS), the French Institute of Health and Medical Research (INSERM), the National Institute of Agronomic Research (INRA), the National Centre for Veterinarians and Food Studies (CNEVA).
Josh Disbrow, Luoxis' President and Chief Executive Officer, stated, "We are excited to partner with these premier European distributors, who will introduce our novel RedoxSYS Diagnostic System to their esteemed customer base and potentially facilitate and accelerate ORP research and development. In line with our current strategy, we expect these agreements to result in high quality research studies using RedoxSYS that further support the clinical potential of ORP and the versatile applicability and broad utility of our RedoxSYS Diagnostic System."
About the RedoxSYS Diagnostic System: The RedoxSYS Diagnostic System is a first-in-class clinical diagnostic platform that measures oxidation-reduction potential (ORP) in the body, a homeostatic measurement of oxidative stress that changes in response to injury or illness. The result of nearly two decades of clinical, scientific and technical R&D, the RedoxSYS System is able to provide the only complete assessment of a patient's oxidative status, which has broad diagnostic application across multiple disease areas where oxidative stress is implicated. Luoxis is currently developing RedoxSYS as a simple, rapid blood test for use in the critical care setting, where its ability to provide an objective measurement of patient illness and predict potential complications may enable physicians to improve resource allocation and align higher levels of care with the most critically injured and ill patients, leading to improved outcomes and optimal workflows.
About Luoxis Diagnostics: Luoxis Diagnostics is an in vitro diagnostics company focused on developing and commercializing its proprietary, CE Marked RedoxSYS Diagnostic System. The company is currently developing RedoxSYS to address the $4+ billion critical care market, where it has the potential to provide hospitals with a single, rapid solution with unmatched diagnostic/prognostic value for conditions with significant medical need, and for which few diagnostic biomarkers exist. Luoxis is conducting initial market development for RedoxSYS in select European territories in order to validate and quantify the clinical value of RedoxSYS for monitoring injury severity and patient oxidative stress following traumatic brain injury, multi-trauma injury, and other critical illnesses. Luoxis is also pursuing U.S. regulatory clearance for RedoxSYS, based on completed and ongoing clinical studies in multiple critical care conditions in the United States, including TBI, multi-trauma injury, stroke, sepsis, and other life-threatening conditions. Luoxis has research collaborations in place with leading centers around the world. Luoxis is a majority-owned subsidiary of Ampio Pharmaceuticals, Inc. For more information, visit www.luoxis.com.
About Ampio Pharmaceuticals: Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.
RedoxSYS and Luoxis are trademarks of Luoxis Diagnostics, Inc.
Forward Looking Statement: Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
For Investors & Media:
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D.: [email protected]; (212) 375-2664
Amy Wheeler: [email protected]; (646) 362-5750
SOURCE Luoxis Diagnostics, Inc.